TP53 and neoplasm: The p62-NRF2-MDM2 axis is involved in tumour progression and programming [96], and MDM2 antagonizes p53 through direct interaction or ubiquitin-dependent degradation [97]; therefore, the inhibition of MDM2 may increase the activity of p53 and restrain p53 mutant cancers [98].